Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 8 | History Defined

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga · Jul 29, 2025

Cancer drug demand drives higher sales for AstraZeneca

Revenues from oncology products made up 43% of the company’s total sales.

Evening Standard · Jul 29, 2025

Business news live: UK food inflation surges again and FTSE 100 results with Greggs facing ‘near-term hurdles’

Stock market news and latest business and finance updates from Tuesday

The Independent UK · Jul 29, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

Barchart · Jul 28, 2025

EU regulators give backing to first-of-its-kind inhaler that is more climate-friendly

Inhalers may be small, but they can make a big impact on the environment.

Euronews · Jul 25, 2025

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

Benzinga · Jul 24, 2025

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will invest $50 billion in the United States by 2030.

Benzinga · Jul 22, 2025

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

International Business Times · Jul 22, 2025

AstraZeneca pledges $50bn investment in the US amid 200% tariff fears

British-Swedish pharmaceutical company AstraZeneca is expanding its presence in the US in a bid to boost sales in its largest market.

Euronews · Jul 22, 2025

AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’

Also: All the news and watercooler chat from Fortune.

Fortune · Jul 22, 2025

AstraZeneca unveils plans for £37bn investment in US amid tariff threats

US President Donald Trump has threatened to impose tariffs of up to 20% on drug imports to boost manufacturing in America and drive down costs.

Evening Standard · Jul 22, 2025

AstraZeneca pledges $50bn US investment ahead of drugs tariffs

Donald Trump is expected to announce tariffs of up to 200% on drugs makers in August

Evening Standard · Jul 22, 2025

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK · Jul 22, 2025

FTSE 100 Live 22 July: Sizewell deal lifts Centrica shares, Compass higher after upgrade

Dealmaking Centrica and Compass were the pick of London’s blue chips today as the FTSE 100 index held its position near to last night’s record close.

Evening Standard · Jul 22, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Jul 22, 2025

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

Benzinga · Jul 21, 2025

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.

Benzinga · Jul 16, 2025

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

Benzinga · Jul 14, 2025

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jul 12, 2025

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

The Independent UK · Jul 11, 2025

Business news live: Price of silver shoots to 14-year high and FTSE 100 falls before weekend

Stock markets updates and business news from Friday

Benzinga · Jul 10, 2025

Cathie Wood Vs. Jim Cramer: TV Host Says Top Ark AI Pick 'Losing Money Hand Over Fist'

When it comes to artificial intelligence stocks, there are multiple that are found in the various portfolios of Ark Funds, led by Cathie Wood.

Evening Standard · Jul 10, 2025

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor

The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.

Evening Standard · Jul 4, 2025

Stocks fade as tariff deadline looms large

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

The Guardian - UK · Jul 2, 2025

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Independent UK · Jul 2, 2025

What AstraZeneca could cost London stock market if it moves to US

IN FULL

1 … 7 8 9 10

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.